Beranda › Karsinoma Nasofaring › Georgia
Uji klinis Karsinoma Nasofaring di Georgia
6 studi untuk Karsinoma Nasofaring mencari peserta di lokasi di Georgia.
Kota di Georgia
Teks studi resmi (Bahasa Inggris)
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
- Emory University Hospital Midtown, Atlanta
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06980038Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
- Emory University Hospital Midtown, Atlanta
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06029270A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Menerima pesertaFase 2
Hingga usia 21 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06064097Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
- Emory Midtown University Hospital/Winship Cancer Institute, Atlanta
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jul 2026 · NCT06662058TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Mar 2026 · NCT06868433Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Feb 2026 · NCT06636734Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.